Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

ohm, I apologize if this has already been addresse

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 155111
(Total Views: 848)
Posted On: 05/24/2024 7:21:29 AM
Posted By: MGK_2
ohm, I apologize if this has already been addressed or answered, but I'd like your opinion regarding the proposed mCRC trial which Dr. Lalezari has prioritized as #1 which also requires a partner.

As you know, from CytoDyn's perspective, the trial cannot fail. It has to be successful and yield unassailable results. Therefore, you would think that they already have seen it work in concert with the medication of the expected partner and that those results were good.

We know that it was tested with Keytruda, but I want to rule out a PD-1 blockade for reasons that you have mentioned already many times, that leronlimab secondarily blocks PD-1 through a primary down regulation of PD-L1. Disregard what I have said in my recent posts. I want to play out another scenario. So, let's disregard Keytruda and Merck right now.

I'm thinking, that given a current FDA approval already exists for regorafenib in MSS mCRC, what credence would you give to a potential fully funded combination trial with this Bayer drug?

The drug is already approved. I think it got through the approval by the skin of its teeth, so just barely. But, if a combination trial is statistically significant, it would be greatly beneficial to both Bayer and CytoDyn as well as the CRO involved.

The problem is that it hasn't yet been tested, unless, in the Basket trial, those few mCRC cases were in patients already using regorafenib. Not sure if any biomarkers were already collected in that basket trial. And the validation of the combination of these drugs is so imperative for a future partnership with Bayer to happen, unless they would just buy us out after learning the single leronlimab arm exceeds the combo.

Regorafenib is being tried with PD-1 blocker and its performance might be improved, but to the point of statistical significance, I'm not sure. Surely Bayer is aware of leronlimab's effectiveness in MSS type tumors and is probably considering a combo trial anyway, but do you think it is important that we know in advance that the combo does work well?

If not Bayer, then with who? Does it need to be a combo? The understanding that leronlimab is effective in the cold or MSS type tumors tells us we will achieve unassailable results in the leronlimab monotherapy arm, but then we would not get a partner. It would put us more in the Buy out category.





(6)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us